Table 1:
General clinical summary of patients including comorbidities
| Characteristics | Total population (n=55) | Survivors (n=35) | Non-Survivors (n=11) | ECMO (n=9) |
|---|---|---|---|---|
| Age, (mean) | 57 | 55 | 63 | 51 |
| Female, (%) | 14 (25%) | 10 (28%) | 2 (18%) | 2 (22%) |
| Race/Ethnicity, (%) | ||||
| Black, (%) | 21 (38%) | 15 (42%) | 4 (36%) | 1 (11%) |
| White, (%) | 17 (30%) | 12 (33%) | 3 (27%) | 3 (27%) |
| Latino, (%) | 14 (25%) | 7 (19%) | 4 (36%) | 4 (44%) |
| Other/Unknown, (%) | 4 (16%) | 2 (5%) | 0 | 1 (11%) |
| Comorbidities | ||||
| Any condition, (%) | 50 (89%) | 32 (89%) | 10 (91%) | 7 (78%) |
| Body Mass Index>30, (%) | 31 (55%) | 22 (61%) | 3 (27%) | 6 (67%) |
| Hypertension, (%) | 23 (41%) | 16 (44%) | 6 (55%) | 5 (56%) |
| Diabetes, (%) | 20 (36%) | 14 (39%) | 4 (36%) | 2 (22%) |
| Cardiovascular disease, (%) | 11 (20%) | 7 (19%) | 4 (36%) | 0 |
| Chronic lung disease, (%) | 10 (18%) | 6 (17%) | 4 (36%) | 0 |
| Renal disease, (%) | 8 (14%) | 3 (8%) | 4 (36%) | 0 |
| Cancer, (%) | 8 (14%) | 3 (8%) | 3 (27%) | 1 (11%) |
| Prior stroke, (%) | 6 (11%) | 5 (14%) | 1 (9%) | 0 |
| COVID-19 treatments | ||||
| Remdesivir, (%) | 45 (80%) | 29 (81%) | 8 (73%) | 90 (100%) |
| Dexamethasone, (%) | 29 (52%) | 19 (53%) | 6 (55%) | 5 (56%) |
| Convalescent Plasma, (%) | 12 (21%) | 7 (19%) | 2 (18%) | 3 (33%) |